# Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

> **NCT00227773** · PHASE2 · WITHDRAWN · sponsor: **Eastern Cooperative Oncology Group**

## Conditions studied

- Gastrointestinal Carcinoid Tumor
- Islet Cell Carcinoma

## Interventions

- **DRUG:** octreotide acetate
- **DRUG:** vatalanib
- **PROCEDURE:** anti-cytokine therapy
- **PROCEDURE:** antiangiogenesis therapy
- **PROCEDURE:** biological therapy
- **PROCEDURE:** endocrine therapy
- **PROCEDURE:** enzyme inhibitor therapy
- **PROCEDURE:** growth factor antagonist therapy
- **PROCEDURE:** hormone therapy
- **PROCEDURE:** protein tyrosine kinase inhibitor therapy
- **PROCEDURE:** somatostatin analogue therapy

## Key facts

- **NCT ID:** NCT00227773
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00227773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00227773, "Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00227773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*